Pasithea Therapeutics Corp. (KTTA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Pasithea Therapeutics reported revenue of $0. Net income was -$20.4M, or -$2.91 per diluted share. Operating activities generated -$15.2M of cash. At fiscal year end, Pasithea Therapeutics held $60.2M in total assets against $5.0M in total liabilities, including $55.2M of cash and equivalents.
Open the full interactive Pasithea Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Pasithea Therapeutics Key Stats
| Share Price | $0.42 |
|---|---|
| Market Cap | $13.6M |
| 52-Week Range | $0.29 – $1.47 |
| Shares Outstanding | 32.1 million (basic, 2026 Q2) |
Pasithea Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $15,062 | $486,559 | $0 | $0 | $0 |
| Cost of Goods Sold | $17,275 | $113,195 | — | — | — |
| Gross Profit | -$2,213 | $373,364 | — | — | — |
| Operating Income | -$4.5M | -$14.8M | -$16.0M | -$14.2M | -$20.9M |
| Pre-Tax Income | -$2.2M | -$13.9M | -$15.5M | -$13.9M | -$20.4M |
| Income Tax | — | — | $453,910 | — | — |
| Net Income | -$2.2M | -$13.9M | -$16.0M | -$13.9M | -$20.4M |
| Diluted EPS | — | -$10.60 | -$0.42 | — | -$2.91 |
Pasithea Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$3.0M | -$10.1M | -$2.9M | -$5.3M |
| Diluted EPS | -$0.41 | -$1.44 | -$0.12 | -$0.16 |
Pasithea Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $53.0M | $33.1M | $16.3M | $6.9M | $55.2M |
| Current Assets | $53.3M | $34.1M | $16.7M | $7.4M | $56.5M |
| Total Assets | $53.3M | $45.2M | $26.1M | $16.1M | $60.2M |
| Current Liabilities | $447,280 | $1.9M | $2.6M | $1.1M | $5.0M |
| Total Liabilities | $1.9M | $2.7M | $2.7M | $1.3M | $5.0M |
| Shareholders' Equity | $51.4M | $42.5M | $23.4M | $14.8M | $55.2M |
Pasithea Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$3.2M | -$14.6M | -$12.8M | -$13.9M | -$15.2M |
| Cash From Investing | -$21,503 | -$2.1M | — | — | $11,000 |
| Cash From Financing | $55.9M | -$3.2M | — | — | $63.5M |
| Free Cash Flow | -$3.2M | -$14.9M | -$12.8M | -$14.0M | — |
Figures from Pasithea Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Pasithea Therapeutics financials page for every line item.
Pasithea Therapeutics Company Profile
| Ticker | KTTA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Miami Beach, Florida |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001841330 |
Frequently Asked Questions
What was Pasithea Therapeutics' revenue in fiscal 2025?
Pasithea Therapeutics (KTTA) reported revenue of $0 for fiscal 2025.
What is Pasithea Therapeutics' annual revenue history?
Pasithea Therapeutics' annual revenue by fiscal year: 2021: $15,062; 2022: $486,559; 2023: $0; 2024: $0; 2025: $0.
What was Pasithea Therapeutics' net income in fiscal 2025?
Pasithea Therapeutics reported net income of -$20.4M for fiscal 2025.
What was Pasithea Therapeutics' earnings per share (EPS) in fiscal 2025?
Pasithea Therapeutics' diluted EPS was -$2.91 for fiscal 2025 (adjusted for any later stock splits).
What was Pasithea Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Pasithea Therapeutics reported revenue of $0.
How many shares of Pasithea Therapeutics are outstanding?
Pasithea Therapeutics reported a weighted average of 32.1 million basic shares outstanding in 2026 Q2.
What is Pasithea Therapeutics' market cap?
Based on its latest closing price, Pasithea Therapeutics (KTTA) has a market capitalization of about $13.6M.
When does Pasithea Therapeutics' fiscal year end?
Pasithea Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Pasithea Therapeutics headquartered?
Pasithea Therapeutics lists its business address in Miami Beach, Florida in its SEC filings.